Video Insights
Video Insights
Advertisement
Melissa BadamoMyeloma | April 10, 2025
Seta Degann, MD, resident physician at George Washington University, described the challenges of diagnosing younger patients.
Nirav Shah, MD, MSHPTransplantation & Cellular Therapy | April 15, 2025
Nirav Shah, MD, MSHP, recently presented at the International Ultmann Chicago Lymphoma Symposium on this subject.
Stephen M/ Ansell, MD, PhDHodgkin Lymphoma | April 10, 2025
Stephen M. Ansell, MD, PhD, explains the importance of making an accurate diagnosis of Hodgkin lymphoma.
Melissa BadamoVideo Insights | April 15, 2025
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
Nikolai Podoltsev, MD, PhDChronic Myeloid Leukemia | April 15, 2025
CML clinical expert Nikolai Podoltsev, MD, PhD, especially addresses the capabilities of tyrosine kinase inhibitors.
Melissa BadamoT-Cell Lymphoma | April 3, 2025
Mark Sorial, PharmD, BCOP, shared the latest research from the Salvia Jain Lab's PETAL Consortium.
Advertisement
Sarah Rutherford, MDFollicular Lymphoma | April 9, 2025
Some major themes for practice include identifying patients at risk for early progression and emphasis on quality of life.
Urvi A. Shah, MDMyeloma | March 27, 2025
Dr. Shah discusses the significance and limitations of two studies on dietary factors and risk of myeloma and MGUS.
Francesca Castro, MS, RDN, CDNMyeloma | March 26, 2025
A plant-based diet is significantly associated with a reduced risk of multiple myeloma.
Janine Joseph, MS, MBAMyeloma | March 24, 2025
A US population-based study investigated the associations between MGUS and various dietary patterns.
Tara Graff, DO, MSAggressive B-Cell Lymphoma | March 10, 2025
The expert panel describes outstanding clinical research needs in DLBCL and what research underway they find exciting.
Tara Graff, DO, MSAggressive B-Cell Lymphoma | March 10, 2025
Expert clinicians describe which factors they consider when selecting between these two interventions for DLBCL management.
Ruemu Birhiray, MDAggressive B-Cell Lymphoma | March 10, 2025
An expert panel discusses utilizing molecular strategies to determine treatment decisions for DLBCL.
Ruemu Birhiray, MDAggressive B-Cell Lymphoma | March 10, 2025
In this DLBCL roundtable, experts share which novel agents or combinations they are most interested in.
Ruemu Birhiray, MDAggressive B-Cell Lymphoma | March 10, 2025
Ruemu Birhiray, MD, leads an expert roundtable on the current treatment pathway in DLBCL.
Ruemu Birhiray, MDAggressive B-Cell Lymphoma | March 10, 2025
The expert panel assesses the current and expected utility for clinicians of MRD in DLBCL management decisions.
Ruemu Birhiray, MDFollicular Lymphoma | April 7, 2025
With insights into next-generation therapies, this discussion explores what’s ahead in the follicular lymphoma landscape.
Ruemu Birhiray, MDFollicular Lymphoma | April 7, 2025
Ruemu Birhiray, MD of Hematology Oncology of Indiana leads the continuation of a roundtable discussion on FL treatment.
Ruemu Birhiray, MDFollicular Lymphoma | April 7, 2025
Three experts analyze data on combination therapy for FL, including efficacy, safety, and strategy adoption.
Greg Nowakowski, MDHodgkin Lymphoma | February 20, 2025
Dr. Nowakowski encourages physicians to refer patients to clinical trials exploring a novel mechanism for CNS lymphoma.
Advertisement
Advertisement